Contacto correo-e:diego.arango@vhir.org
---
SE BUSCA:
Un candidato/a altamente motivado/a para realizar el doctorado en el laboratorio de Oncología Molecular del Instituto de Investigaciones Vall d’Hebron (http://www.vhir.org/gr/
SE OFRECE:
- Sueldo bruto de 19.900,00 euros al año.
- Contrato laboral de tres años.
- Ambiente académico activo y estimulante
REQUISITOS DE LOS CANDIDATOS:
- Tener el título de máster en un área relacionada con fecha posterior al 1 de enero de 2011.
- La nota media del expediente académico debe ser superior a dos (escala 1-4). Para candidatos con titulaciones extranjeras, usar la tabla de conversión correspondiente: http://tinyurl.com/9kh5h36 o http://tinyurl.com/9p67qt7.
- Tener buenos conocimientos de lengua inglesa.
- Preferiblemente tener experiencia en técnicas de biología molecular y biología del cáncer.
CONTACTO:
Contactar antes del 19 de diciembre del 2012 con el Dr. Diego Arango (diego.arango@vhir.org)
==============================
PhD POSITION – MOLECULAR ONCOLOGY - BARCELONA
We are currently seeking a full-time funded PhD student for a predoctoral position at the Group of Molecular Oncology at Vall d’Hebron Research Institute, Barcelona, Spain (http://www.vhir.org/gr/
WE OFFER
- Gross annual salary: 19,900.00 Euros.
- Three year contract:
- Active and stimulating academic environment
THE CANDIDATES MUST:
- Have a Master’s degree completed after January the 1st 2011.
- The average grade of the Bachelor’s degree should be >2 (scale 1-4). Please, use the appropriate table for your grade conversion: http://tinyurl.com/9kh5h36 or http://tinyurl.com/9p67qt7.
- Be fluent in English language.
- Experience with molecular/cell biology techniques in the field of cancer biology.
CONTACT
Please, contact Dr. Diego Arango before 19-12-2012 at diego.arango@vhir.org
----------------
Información complementaria de la oferta:
SELECCIÓN DE PUBLICACIONES
51.- Veronica Davalos, Lucia Suarez-Lopez, Julio Castano, Anthea Messent, Ibane Abasolo, Yolanda Fernandez, Angel Guerra-Moreno, Eloy Espin, Manel Armengol, Eva Musulen, Aurelio Ariza, Joan Sayos, Diego Arango and Simo Schwartz. hSMC, a Core Subunit of Human Condensin Complex, is a Novel Transcriptional Target of the Wnt Signaling Pathway and a New Therapeutic Target. J Biol Chem. 2012 Oct 24. [Epub ahead of print]
50.- Mazzolini R, Rodrigues P, Bazzocco S, Dopeso H, Ferreira AM, Mateo-Lozano S, Andretta E, Woerner SM, Alazzouzi H, Landolfi S, Hernandez-Losa J, Macaya I, Suzuki H, Cajal SR, Mooseker MS, Mariadason JM, Gebert J, Hofstra RM, Reventós J, Yamamoto H, Jr SS, Arango D. Brush border myosin Ia inactivation in gastric but not endometrial tumors. Int J Cancer. 2012 Sep 24. doi: 10.1002/ijc.27856. [Epub ahead of print]
Arango D, Al-Obaidi S, Williams DS, Dopeso H, Mazzolini R, Corner G, Byun DS, Carr AA, Murone C, Tögel L, Zeps N, Aaltonen LA, Iacopetta B, Mariadason JM. Villin Expression Is Frequently Lost in Poorly Differentiated Colon Cancer. Am J Pathol. 2012 Feb 17. [Epub ahead of print]
Mazzolini R, Dopeso H, Mateo-Lozano S, Chang W, Rodrigues P, Bazzocco S, Alazzouzi H, Landolfi S, Hernández-Losa J, Andretta E, Alhopuro P, Espín E, Armengol M, Tabernero J, Ramón Y Cajal S, Kloor M, Gebert J, Mariadason JM, Schwartz S Jr, Aaltonen LA, Mooseker MS, Arango D. Brush border Myosin Ia has tumor suppressor activity in the intestine. Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1530-5. Epub 2012 Jan 18.
Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, Arango D. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clinical Cancer Research. 2010 Apr 15;16(8):2375-82.
Alhopuro P, Phichith D, Tuupanen S, Sammalkorpi H, Nybondas M, Saharinen J, Robinson JP, Yang Z, Chen LQ, Orntoft T, Mecklin JP, Järvinen H, Eng C, Moeslein G, Shibata D, Houlston RS, Lucassen A, Tomlinson IPM, Launonen V, Ristimäki A, Arango D, Karhu A, Sweeney HL, and Aaltonen LA. Unregulated smooth muscle myosin in human intestinal neoplasia. Proceedings of the National Academy of Sciences, 2008; 105(14):5513-8. Epub 2008 Apr 7.
Davalos v, Dopeso H, Velho S, Monteiro Ferreira A, Cirnes L, Díaz-Chico N, Bilbao C, Ramírez R, Rodríguez G, Falcón O, León L, Niessen R, Keller G, Dallenbach-Hellweg G, Espín E, Armengol M, Perucho M, Imai K, Yamamoto H, Gebert JF, Díaz-Chico JC, Hofstra RM, Woerner SM, Seruca R, Schwartz Jr. S, Arango D. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene, 2007;26(2):308-11
Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz Jr. S, Arango D. EPHB4 and survival of colorectal cancer patients. Cancer Research, 2006; 66(18):8943-8948
Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Arango D, Aaltonen LA, Schwartz S Jr, Esteller M. A truncating mutation of HDAC2 in human cancers confer resistance to histone deacetylase inhibition. Nature Genetics, 2006;38(5):566-9
Paroder V, Spencer SR, Paroder M, Arango D, Schwartz Jr S, Mariadason JM, Augenlicht LH, Eskandari S, and Carrasco N. Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT. Proceedings of the National Academy of Sciences, 2006 May 9;103(19):7270-5
Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ, Konrad L, Laiho P, Espín E, Armengol M, Imai K, Yamamoto H, Mariadason JM, Gebert JF, Aaltonen LA, Schwartz S Jr., Arango D. Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Research, 2005; 65(22):10170-3
